Evolus ROA 2016-2024 | EOLS
Current and historical return on assets (ROA) values for Evolus (EOLS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Evolus ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2024-12-31 | $-0.05B | $0.23B | -21.67% |
| 2024-09-30 | $-0.06B | $0.23B | -25.03% |
| 2024-06-30 | $-0.05B | $0.23B | -25.95% |
| 2024-03-31 | $-0.06B | $0.23B | -31.91% |
| 2023-12-31 | $-0.06B | $0.19B | -36.15% |
| 2023-09-30 | $-0.06B | $0.17B | -37.33% |
| 2023-06-30 | $-0.07B | $0.17B | -37.71% |
| 2023-03-31 | $-0.07B | $0.16B | -38.27% |
| 2022-12-31 | $-0.07B | $0.18B | -36.86% |
| 2022-09-30 | $-0.08B | $0.19B | -35.83% |
| 2022-06-30 | $-0.08B | $0.21B | -34.51% |
| 2022-03-31 | $-0.07B | $0.22B | -30.44% |
| 2021-12-31 | $-0.05B | $0.26B | -21.63% |
| 2021-09-30 | $-0.14B | $0.22B | -68.21% |
| 2021-06-30 | $-0.13B | $0.24B | -64.23% |
| 2021-03-31 | $-0.14B | $0.16B | -70.53% |
| 2020-12-31 | $-0.16B | $0.21B | -78.18% |
| 2020-09-30 | $-0.07B | $0.22B | -30.98% |
| 2020-06-30 | $-0.08B | $0.20B | -39.90% |
| 2020-03-31 | $-0.10B | $0.21B | -47.62% |
| 2019-12-31 | $-0.09B | $0.24B | -42.98% |
| 2019-09-30 | $-0.09B | $0.18B | -45.19% |
| 2019-06-30 | $-0.07B | $0.20B | -37.48% |
| 2019-03-31 | $-0.05B | $0.22B | -29.23% |
| 2018-12-31 | $-0.05B | $0.17B | -30.46% |
| 2018-09-30 | $-0.03B | $0.18B | -20.55% |
| 2018-06-30 | $-0.02B | $0.12B | -20.95% |
| 2018-03-31 | $-0.01B | $0.13B | -10.04% |
| 2017-12-31 | $-0.01B | $0.15B | -13.16% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.746B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $226.329B | 27.30 |
| Boston Scientific (BSX) | United States | $151.960B | 38.05 |
| Stryker (SYK) | United States | $141.576B | 30.43 |
| EssilorLuxottica (ESLOY) | France | $131.433B | 0.00 |
| Medtronic (MDT) | Ireland | $108.503B | 15.84 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.360B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.382B | 26.36 |
| ResMed (RMD) | United States | $34.859B | 26.18 |
| GE HealthCare Technologies (GEHC) | United States | $31.175B | 15.16 |
| Agilent Technologies (A) | United States | $30.637B | 20.24 |
| Terumo (TRUMY) | Japan | $28.678B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 16.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.336B | 12.85 |
| Insulet (PODD) | United States | $17.646B | 75.46 |
| Baxter (BAX) | United States | $15.890B | 11.43 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.790B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Demant (WILYY) | Denmark | $7.600B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.119B | 17.50 |
| Bio-Rad Laboratories (BIO) | United States | $6.788B | 23.50 |
| Prestige Consumer Healthcare (PBH) | United States | $4.059B | 19.37 |
| Perrigo (PRGO) | Ireland | $3.496B | 10.01 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.378B | 28.78 |
| Haemonetics (HAE) | United States | $3.214B | 15.12 |
| Envista Holdings (NVST) | United States | $2.745B | 22.19 |
| GN Store Nord (GNNDY) | Denmark | $2.260B | 15.23 |
| LeMaitre Vascular (LMAT) | United States | $2.092B | 47.73 |
| QuidelOrtho (QDEL) | United States | $1.928B | 16.15 |
| AtriCure (ATRC) | United States | $1.715B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.258B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.250B | 19.63 |
| BioLife Solutions (BLFS) | United States | $1.174B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.129B | 10.87 |
| Neogen (NEOG) | United States | $1.092B | 13.97 |
| InMode (INMD) | Israel | $1.003B | 9.18 |
| Phibro Animal Health (PAHC) | United States | $0.765B | 11.73 |
| Curaleaf Holdings (CURLF) | Canada | $0.596B | 0.00 |
| CeriBell (CBLL) | United States | $0.587B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.574B | 0.00 |
| Owens & Minor (OMI) | United States | $0.541B | 4.61 |
| Valneva SE (VALN) | France | $0.539B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.526B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.493B | 0.00 |
| Surmodics (SRDX) | United States | $0.442B | 0.00 |
| Omeros (OMER) | United States | $0.419B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.414B | 0.00 |
| SNDL (SNDL) | Canada | $0.389B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.357B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.346B | 15.02 |
| Verano Holdings (VRNOF) | United States | $0.307B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.286B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 24.82 |
| ZimVie (ZIMV) | United States | $0.264B | 15.78 |
| Aurora Cannabis (ACB) | Canada | $0.261B | 46.40 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.256B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.237B | 0.00 |
| Quanterix (QTRX) | United States | $0.235B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.220B | 0.00 |
| High Tide (HITI) | Canada | $0.196B | 0.00 |
| Biote (BTMD) | United States | $0.194B | 4.43 |
| TriSalus Life Sciences (TLSI) | United States | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.89 |
| Brainsway (BWAY) | Israel | $0.168B | 52.29 |
| Organigram Global (OGI) | Canada | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.99 |
| Jin Medical (ZJYL) | China | $0.140B | 0.00 |
| Exagen (XGN) | United States | $0.123B | 0.00 |
| Agape ATP (ATPC) | $0.121B | 0.00 | |
| TerrAscend (TSNDF) | Canada | $0.108B | 0.00 |
| MacroGenics (MGNX) | United States | $0.101B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.095B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| Veru (VERU) | United States | $0.081B | 0.00 |
| Fonar (FONR) | United States | $0.078B | 10.86 |
| Cytosorbents (CTSO) | United States | $0.070B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.068B | 0.00 |
| Zynex (ZYXI) | United States | $0.067B | 0.00 |
| United Health Products (UEEC) | United States | $0.066B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 55.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 11.11 |
| Apyx Medical (APYX) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |